Trailing-twelve-month (TTM) revenue is $332.77 Billion with a year-over-year growth of +5.09%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q4 FY2025Period ended 2025-09-30 | $83,728,554,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-25 |
| Q1 FY2026Period ended 2025-12-31 | $85,932,016,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-04 |
| Q2 FY2026Period ended 2026-03-31 | $78,355,916,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-06 |
| Q3 FY2026Period ended 2026-06-30 | $84,754,837,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-05 |
| TTM revenue | $332,771,323,000 |
Current P/S: $62,565,000,064 market capitalization ÷ $332,771,323,000 TTM revenue = 0.19x.
Market capitalization source: FMP quote. Quote observed 2026-09-11T20:00:03.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q3 FY2026 (2026-06-30): $84.75B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-12T00:15:25.379Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-10.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-09-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-09-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-09-30 · USD | FY20212021-09-30 · USD | FY20222022-09-30 · USD | FY20232023-09-30 · USD | FY20242024-09-30 · USD | FY20252025-09-30 · USD |
|---|---|---|---|---|---|---|
| Animal Health | $4.2B | $4.7B | $4.2B | $5.0B | $5.4B | $5.7B |
| International Healthcare Solutions | $3.3B | $11.3B | $26.5B |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-09-30 · USD | FY20212021-09-30 · USD | FY20222022-09-30 · USD | FY20232023-09-30 · USD | FY20242024-09-30 · USD | FY20252025-09-30 · USD |
|---|---|---|---|---|---|---|
| International Healthcare Solutions | N/A | N/A | $26.5B | $27.4B | $28.6B | $30.4B |
| Other Segments | $7.5B | $16.0B | N/A |
$332.77B
$332.77 Billion
+5.09%
vs. $316.65B a year ago (TTM)
+10.25%
5 Year compound annual growth rate
1 Year
+5.09%
3 Year
+9.36%
5 Year
+10.25%
10 Year
+8.68%
15 Year
+10.01%
20 Year
+8.99%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $321.33B | +$27.37B | +9.31% |
| 2024 | $293.96B | +$31.79B | +12.12% |
| 2023 | $262.17B | +$23.59B | +9.89% |
| 2022 | $238.59B | +$24.60B | +11.50% |
| 2021 | $213.99B | +$24.09B | +12.69% |
| 2020 |
TTM Growth
+5.09%
3-Year CAGR
+9.36%
5-Year CAGR
+10.25%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-12T00:15:25.379Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-10.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $28.6B |
| $30.4B |
| Other Segments | $7.5B | N/A | N/A | N/A | N/A | N/A |
|---|
| Pharmaceutical Distribution | $182.5B | N/A | $182.2B | $229.7B | $260.0B | $285.3B |
|---|
| N/A |
| N/A |
| N/A |
| U.S. Healthcare Solutions | N/A | N/A | $186.4B | $234.8B | $265.3B | $291.0B |
|---|
| $189.89B |
| +$10.30B |
| +5.74% |
| 2019 | $179.59B | +$11.65B | +6.94% |
| 2018 | $167.94B | +$14.80B | +9.66% |
| 2017 | $153.14B | +$6.29B | +4.29% |
| 2016 | $146.85B | +$10.89B | +8.01% |
